glp-1 insurance coverage news in Employer Plans Could Nearly Double in 2024 At the beginning of this

95% CI, 1.21 to 2.67) [35]

Nigeria 19.3.9.4

Tier 2: Cardiovascular Disease and Sleep Apnea Covered in Most States (Required Since 2024) Two newer FDA approvals expanded mandatory Medicaid coverage: Wegovy for cardiovascular risk reduction FDA-approved in March 2024 to reduce the risk of heart attack, stroke, and cardiovascular death in overweight or obese adults with established cardiovascular disease

Haqq L, McFarlane J, Dieberg G, Smart N

Patel continued, We intend to leverage Forzets unique value proposition by recommending it as an adjunct solution for patients prescribed GLP-1 agonist drugs via pop-ups through our EinsteinRx hub technology at the point-of-sale in Wellgistics Pharmacy Network pharmacies